CompletedPhase 3NCT03154476
Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study
Studying Fontan-associated liver disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Alexander C EgbeMayo Clinic
- Intervention
- Sildenafil(drug)
- Enrollment
- 20 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2019
Study locations (1)
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03154476 on ClinicalTrials.govOther trials for Fontan-associated liver disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07009132Cholate Clearance in Fontan and Heart FailureHepQuant, LLC
- RECRUITINGPHASE1NCT06324396IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver DiseaseChildren's Mercy Hospital Kansas City
- RECRUITINGNCT05213598Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity AssessmentNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- ACTIVE NOT RECRUITINGNCT03914196Fontan Associated Liver DiseaseChildren's Hospital Medical Center, Cincinnati